Thermo Fisher Scientific Inc
Gesloten
SectorGezondheidszorg
464.64 0.93
Overzicht
Wijziging aandelenprijs
24u
Min
464.64
Max
467.51
Inkomsten | -314M 1.7B |
|---|---|
Verkoop | -1.2B 11B |
K/W Sectorgemiddelde | 26.043 49.712 |
EPS | 5.44 |
Dividendrendement | 0.38 |
Winstmarge | 15.048 |
Werknemers | 125,000 |
EBITDA | -905M 2.3B |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +28.05% upside |
Dividendrendement Sectorgemiddelde | 0.38% 2.36% |
|---|---|
Volgende Winsten | 22 jul 2026 |
Volgende dividenddatum | 15 jul 2026 |
Volgende Ex Dividend datum | 14 sep 2026 |
Marktkapitalisatie | -19B 176B |
|---|---|
Vorige openingsprijs | 463.71 |
Vorige sluitingsprijs | 464.64 |
Nieuwssentiment
By Acuity
36%
64%
82 / 342 Rangschikking in Healthcare
Thermo Fisher Scientific Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar